• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过将四价流感疫苗与CpG HP021联合使用来提高其抗体水平和T细胞活性。

Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021.

作者信息

Ji Jia, Chen Lei, Wu Zhigang, Tang Taoming, Zhu Linwei, Zhu Miaojin, Chen Yan, Lu Xiangyun, Yao Hangping

机构信息

State Key Laboratory for Diagnosis, Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China.

Jinan Microecological Biomedicine Shandong Laboratory, Jinan, 250000, China.

出版信息

Sci Rep. 2024 Dec 28;14(1):31424. doi: 10.1038/s41598-024-83026-x.

DOI:10.1038/s41598-024-83026-x
PMID:39733119
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11682164/
Abstract

Influenza virus infections are a serious danger to people's health worldwide as they are responsible for seasonal flu outbreaks. There is an urgent need to improve the effectiveness and durability longevity of the immune response to influenza vaccines. We synthesized the CpG HP021 and examined the impact of it on the immune response to an influenza vaccine. In BALB/c mice, hemagglutination inhibition (HI) titers to the vaccine were increased four- to eightfold against H1N1, H3N2, BV, and BY viruses by 3 μg IIV4 + 40 μg CpG HP021 compared with those of the non-adjuvanted IIV4 group, and the CpG HP021 group had a broader HI activity. Additionally, the immune response was directed towards Type 1 T helper (Th1) cells due to the CpG HP021 adjuvant. The CpG HP021-adjuvanted IIV4 induced a higher number of T cells secreting interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α), and increased the percentage of effector memory T cells in mice. In SD rats, the immune responses induced by IIV4 with CpG HP021 were similar to those in BALB/c mice. The development of CpG HP021 may expand the options for adjuvants in vaccines against infectious diseases.

摘要

流感病毒感染对全球人们的健康构成严重威胁，因为它们会引发季节性流感疫情。迫切需要提高流感疫苗免疫反应的有效性和持久寿命。我们合成了CpG HP021，并研究了其对流感疫苗免疫反应的影响。在BALB/c小鼠中，与未添加佐剂的IIV4组相比，3μg IIV4 + 40μg CpG HP021使针对H1N1、H3N2、BV和BY病毒的疫苗血凝抑制（HI）滴度提高了4至8倍，并且CpG HP021组具有更广泛的HI活性。此外，由于CpG HP021佐剂，免疫反应针对1型辅助性T（Th1）细胞。添加CpG HP021的IIV4诱导分泌干扰素γ（IFN-γ）和肿瘤坏死因子α（TNF-α）的T细胞数量增加，并提高了小鼠中效应记忆T细胞的百分比。在SD大鼠中，添加CpG HP021的IIV4诱导的免疫反应与BALB/c小鼠中的相似。CpG HP021的开发可能会扩大针对传染病疫苗佐剂的选择范围。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/8f05c5c3cde3/41598_2024_83026_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/cc42cdcb99b2/41598_2024_83026_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/d74b851cee3b/41598_2024_83026_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/c55c5e29749f/41598_2024_83026_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/13b6376c6b90/41598_2024_83026_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/a84fbcfdaccd/41598_2024_83026_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/8f05c5c3cde3/41598_2024_83026_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/cc42cdcb99b2/41598_2024_83026_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/d74b851cee3b/41598_2024_83026_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/c55c5e29749f/41598_2024_83026_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/13b6376c6b90/41598_2024_83026_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/a84fbcfdaccd/41598_2024_83026_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de14/11682164/8f05c5c3cde3/41598_2024_83026_Fig6_HTML.jpg

相似文献

1
Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021.通过将四价流感疫苗与CpG HP021联合使用来提高其抗体水平和T细胞活性。
Sci Rep. 2024 Dec 28;14(1):31424. doi: 10.1038/s41598-024-83026-x.
2
Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.不同佐剂在肌肉注射和鼻内给药途径下对去污剂裂解A/H3N2流感疫苗诱导的小鼠体液免疫和细胞免疫反应的影响。
Clin Vaccine Immunol. 2012 Feb;19(2):209-18. doi: 10.1128/CVI.05441-11. Epub 2011 Dec 21.
3
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.用于在小鼠中诱导对流感疫苗产生强效、持久抗体和T细胞反应的联合佐剂。
Vaccine. 2008 Jan 24;26(4):552-61. doi: 10.1016/j.vaccine.2007.11.054. Epub 2007 Dec 7.
4
Broadly Protective CD8 T Cell Immunity to Highly Conserved Epitopes Elicited by Heat Shock Protein gp96-Adjuvanted Influenza Monovalent Split Vaccine.热休克蛋白 gp96 佐剂流感单价裂解疫苗诱导广泛保护性 CD8 T 细胞免疫应答针对高度保守表位。
J Virol. 2021 May 24;95(12). doi: 10.1128/JVI.00507-21.
5
Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant.通过明矾：CpG复合物佐剂增强COVID-19疫苗中的免疫反应。
Antiviral Res. 2024 Sep;229:105954. doi: 10.1016/j.antiviral.2024.105954. Epub 2024 Jul 2.
6
Mastoparan-7 adjuvanted COBRA H1 and H3 hemagglutinin influenza vaccines.Mastoparan-7 佐剂化 COBRA H1 和 H3 血凝素流感疫苗。
Sci Rep. 2024 Jun 14;14(1):13800. doi: 10.1038/s41598-024-64351-7.
7
Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.NKT细胞激动剂α-半乳糖神经酰胺的辅助使用可增强基于M2的DNA疫苗的免疫原性及对甲型流感病毒的保护性免疫。
Arch Virol. 2017 May;162(5):1251-1260. doi: 10.1007/s00705-017-3230-7. Epub 2017 Jan 24.
8
Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development.新型 PELC/CpG 佐剂配制的 H7N9 亚单位疫苗用重组血凝素蛋白。
Antiviral Res. 2017 Oct;146:213-220. doi: 10.1016/j.antiviral.2017.09.014. Epub 2017 Sep 22.
9
MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).MF59乳液是一种用于合成Toll样受体4激动剂（E6020）的有效递送系统。
Pharm Res. 2009 Jun;26(6):1477-85. doi: 10.1007/s11095-009-9859-5. Epub 2009 Mar 3.
10
Adjuvant-free, self-assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses.不含佐剂、自组装的铁蛋白纳米颗粒疫苗与携带M1和PADRE表位的流感病毒血凝素蛋白偶联，可引发交叉保护性免疫反应。
Front Immunol. 2025 Jan 31;16:1519866. doi: 10.3389/fimmu.2025.1519866. eCollection 2025.

引用本文的文献

1
One Health adjuvant selection for vaccines against zoonotic infections.针对人畜共患病感染疫苗的“同一健康”佐剂选择
Explor Med. 2025;6. doi: 10.37349/emed.2025.1001316. Epub 2025 May 7.

本文引用的文献

1
Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant.通过明矾：CpG复合物佐剂增强COVID-19疫苗中的免疫反应。
Antiviral Res. 2024 Sep;229:105954. doi: 10.1016/j.antiviral.2024.105954. Epub 2024 Jul 2.
2
Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax.不同 AV7909 剂量方案在非临床肺炭疽模型中的疗效。
Hum Vaccin Immunother. 2023 Dec 15;19(3):2290345. doi: 10.1080/21645515.2023.2290345. Epub 2023 Dec 19.
3
A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine.
TLR9 激动剂与 Alum 佐剂 H7N9 灭活全病毒疫苗协同增强保护性免疫。
Emerg Microbes Infect. 2023 Dec;12(2):2249130. doi: 10.1080/22221751.2023.2249130.
4
Development of an mRNA vaccine against a panel of heterologous H1N1 seasonal influenza viruses using a consensus hemagglutinin sequence.基于血凝素共识序列的一组异源季节性 H1N1 流感病毒 mRNA 疫苗的研制。
Emerg Microbes Infect. 2023 Dec;12(1):2202278. doi: 10.1080/22221751.2023.2202278.
5
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.BA.1 和 BA.4/BA.5 二价 SARS-CoV-2 加强免疫的免疫原性：COVAIL 随机临床试验的初步结果。
Clin Infect Dis. 2023 Aug 22;77(4):560-564. doi: 10.1093/cid/ciad209.
6
New-age vaccine adjuvants, their development, and future perspective.新型疫苗佐剂及其研发与未来展望。
Front Immunol. 2023 Feb 24;14:1043109. doi: 10.3389/fimmu.2023.1043109. eCollection 2023.
7
A Plant-Produced Porcine Parvovirus 1-82 VP2 Subunit Vaccine Protects Pregnant Sows against Challenge with a Genetically Heterologous PPV1 Strain.一种植物生产的猪细小病毒1型-82 VP2亚单位疫苗可保护怀孕母猪免受基因异源PPV1毒株的攻击。
Vaccines (Basel). 2022 Dec 26;11(1):54. doi: 10.3390/vaccines11010054.
8
Safety and Immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine given with and without AS03 or MF59 adjuvants in healthy adults.在健康成年人中，单剂量甲型H5N8流感病毒灭活疫苗与AS03或MF59佐剂联合使用或不使用佐剂时的安全性和免疫原性。
Clin Infect Dis. 2023 Jan 5. doi: 10.1093/cid/ciac983.
9
Overcoming Aging-Associated Poor Influenza Vaccine Responses with CpG 1018 Adjuvant.使用CpG 1018佐剂克服与衰老相关的流感疫苗反应不佳问题。
Vaccines (Basel). 2022 Nov 10;10(11):1894. doi: 10.3390/vaccines10111894.
10
Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study.在先前接受过乙型肝炎疫苗接种但未达到血清保护的接受血液透析的成年人中，与 HepB-Eng（Engerix-B®）和 HepB-AS04（Fendrix®）相比，乙型肝炎疫苗 HepB-CpG（HEPLISAV-B®）加强剂量的免疫原性和安全性：一项随机、多中心 3 期研究结果。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2136912. doi: 10.1080/21645515.2022.2136912. Epub 2022 Oct 21.